There is an ongoing need to develop strategic combinations of therapeutic agents to prevent
type 1 diabetes (T1D) or to preserve islet β-cell mass in new-onset disease. Although clinical …

It has been 30 years since the discovery of the nonobese diabetic (NOD) mouse (1974) at
the Shionogi Research Laboratories in Osaka, Japan (Hanafusa et al., 1994). In this time the …

Type 1 diabetes | Nature Immunology Skip to main content Thank you for visiting nature.com.
You are using a browser version with limited support for CSS. To obtain the best experience …

T1DM (Type I diabetes mellitus) results from selective destruction of the insulin-producing β-
cells of the pancreas by the immune system, and is characterized by hyperglycaemia and …

Type 1 diabetes is an autoimmune disease whose clinical onset signifies a lifelong
requirement for insulin therapy and increased risk of medical complications. To increase the …

Abstract Type 1 diabetes (T1D) is a complex polygenic disease that is triggered by various
environmental factors in genetically susceptible individuals. The emphasis placed on …

Our understanding of the genetics, aetiology and pathogenesis of Type 1 Diabetes (T1D)
was propelled by the discovery of animal models of T1D in the late 1970s and early 1980s …

Most natural history models for type 1 diabetes (T1D) propose that overt hyperglycemia
results after a progressive loss of insulin-secreting β-cell mass and/or function. To …

There are many rodent models of autoimmune diabetes that have been used to study the
pathogenesis of human type 1 diabetes (T1D), including the non‐obese diabetic (NOD) …

In type 1 diabetes mellitus (T1DM), also known as autoimmune diabetes, the pathogenic
destruction of the insulin-producing pancreatic β-cells is under the control of and influenced …